scholarly journals Detection of Deep Vein Thrombosis by Follow-up Indirect Computed Tomography Venography after Pulmonary Embolism

2018 ◽  
Vol 81 (1) ◽  
pp. 49
Author(s):  
Hye Jin Lee ◽  
Seung-Ick Cha ◽  
Kyung-Min Shin ◽  
Jae-Kwang Lim ◽  
Seung-Soo Yoo ◽  
...  
2020 ◽  
Vol 4 (2) ◽  
pp. 432-439 ◽  
Author(s):  
Derek Weycker ◽  
Gail DeVecchis Wygant ◽  
Jennifer D. Guo ◽  
Theodore Lee ◽  
Xuemei Luo ◽  
...  

Abstract In the phase 3 trial Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy, apixaban was noninferior to enoxaparin, overlapped and followed by warfarin, in the treatment of venous thromboembolism (VTE) with significantly less bleeding; in a real-world evaluation, risks for bleeding and recurrent VTE were lower with apixaban vs warfarin plus parenteral anticoagulant (PAC) bridge therapy. The present study extends this research by comparing outcomes over time and within selected subgroups. A retrospective observational cohort design and 4 US private health care claims databases were used. Study population included patients who initiated outpatient treatment with apixaban or warfarin (plus PAC bridge therapy) for VTE. Major bleeding, clinically relevant nonmajor (CRNM) bleeding, and recurrent VTE were compared during the 180-day follow-up period, at selected follow-up time points (days 21, 90, 180), and within subgroups (pulmonary embolism [PE] with or without deep vein thrombosis [DVT], DVT only, provoked VTE, unprovoked VTE) using multivariable shared frailty models. Study population consisted of 20 561 apixaban patients and 35 080 warfarin patients; baseline characteristics were comparable. Overall, at selected follow-up time points, and within the aforementioned subgroups, adjusted risks were lower among apixaban vs warfarin patients: major bleeding, by 27% to 39%, CRNM bleeding, by 17% to 28%, and recurrent VTE, by 25% to 39% (all P ≤ .01). In this real-world study of VTE patients, risks of bleeding and recurrent VTE were lower among apixaban (vs warfarin) patients during the 180-day follow-up period, at selected follow-up time points, and within subgroups defined by index VTE episode.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2306-2306
Author(s):  
Inna Tsoran-Rosenthal ◽  
Gleb Sakharov ◽  
Benjamin Brenner ◽  
Karine Rivron-Guillot ◽  
Adriana VisonÁ ◽  
...  

Abstract Abstract 2306 Background: One in every three patients with deep vein thrombosis (DVT) may have silent pulmonary embolism (PE), but its clinical relevance has not been thoroughly studied. Methods: We used the RIETE Registry data to compare the clinical characteristics, diagnostic tests, and 3-month outcome in 842 patients with proximal DVT in the lower limbs and silent PE at baseline, 1533 with DVT without PE, and 585 patients with DVT and symptomatic PE. Results: On admission, a minority of DVT patients (with or without silent PE) presented with hypoxemia (9.0% vs. 6.4%, respectively), or typical PE signs on the chest X-ray (25% vs. 22%) or electrocardiogram (23% vs. 17%). Patients with symptomatic PE more frequently presented with hypoxemia (30%) or had PE signs on the chest X-ray (41%) or electrocardiogram (37%). After the initial 15 days of follow up the incidence of PE was higher among patients with DVT and silent PE compared to those with symptomatic PE (0.95% vs. 0.17%).During the first 90 days of anticoagulant therapy, patients with DVT without PE had a lower incidence of recurrent PE than bleeding (1.0% and 2.9%, respectively). Of note, an excessive risk for bleeding was observed during the first 2 weeks of therapy among patients without PE. Incidence of recurrent PE and major bleeding was similar in DVT patients with silent PE (1.8% and 1.9%) and in those with symptomatic PE (2.6% and 2.7%). Conclusions: Most DVT patients with silent PE have no hypoxemia, chest X-ray signs or electrocardiographic evidence suggestive of embolism. Frequency of recurrent PE was higher among patients with silent PE at the initial 15 days of follow up. In contrast to other subgroups, in DVT patients without PE at baseline, the incidence of major bleeding far exceeded that of PE development during follow up. Disclosures: No relevant conflicts of interest to declare.


2019 ◽  
Vol 8 (6) ◽  
pp. 899 ◽  
Author(s):  
Elena-Mihaela Cordeanu ◽  
Hélène Lambach ◽  
Marie Heitz ◽  
Julie Di Cesare ◽  
Corina Mirea ◽  
...  

Background: The prognostic significance of coexisting deep vein thrombosis (DVT) in acute pulmonary embolism (PE) is controversial. This study aimed to provide routine patient care data on the impact of this association on PE severity and 3-month outcomes in a population presenting with symptomatic venous thromboembolism (VTE) from the REMOTEV registry. Methods and Results: REMOTEV is a prospective, non-interventional study of patients with acute symptomatic VTE, treated with direct oral anticoagulants (DOACs) or standard anticoagulation (vitamin K antagonists (VKA) or parenteral heparin/fondaparinux alone) for at least 3 months. From 1 November 2013 to 28 February 2018, among 1241 consecutive patients included, 1192 had a follow-up of at least 3 months and, among them, 1037 had PE with (727) or without DVT (310). The median age was 69 (55–80, 25th–75th percentiles). Patients with PE-associated DVT had more severe forms of PE (p < 0.0001) and, when DVT was present, proximal location was significantly correlated to PE severity (p < 0.01). However, no difference in all-cause mortality rate (hazard ratio (HR) 1.36 (CI 95% 0.69–2.92)), nor in the composite criterion of all-cause mortality and recurrence rate (HR 1.56 (CI 95% 0.83–3.10)) was noted at 3 months of follow-up. Conclusion: In REMOTEV, coexisting DVT was associated with a higher severity of PE, with no impact on short-term prognosis.


2016 ◽  
Vol 01 (04) ◽  
pp. 032-035
Author(s):  
Seetharam Vankudoth ◽  
Madhurima banoth

AbstractVenous thromboembolism, causing Pulmonary Embolism (PE), is one of the major cardiovascular causes of death. We are reporting three cases of pulmonary thromboembolism without deep vein thrombosis and with normal levels of homocysteine, protein C and S, anti-thrombin III levels. All three cases managed with thrombolysis with streptokinase, out of three cases two cases systemic thrombolysis given and one case catheter guided thrombolysis given and discharged on oral anticoagulant with target range of PT with INR 2-3.on subsequent follow-up one case was diagnosed lymphoma and he was treated successfully in our institution.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1979-1979
Author(s):  
Michael J. Kovacs ◽  
Jeffrey D.E. Hawel ◽  
Janelle F. Rekman ◽  
Alejandro Lazo-Langner

Abstract Background: Acute pulmonary embolism (PE) is a common medical problem in outpatient clinics and emergency rooms. Treatment with heparin and warfarin is well established and effective. In some centres (such as ours) eligible patients with PE are treated as outpatients, however many centres remain reluctant to do so. We review our experience with outpatient treatment of acute PE. Methods: We reviewed hospital charts for all inpatients and thrombosis clinic charts for all outpatients with a diagnosis of acute PE that was made prior to a decision on hospital admission from January 1, 2003 to January 30, 2008. All diagnoses were objectively proven by high probability V/Q scan or non-diagnostic V/Q scan with positive compression U/S or segmental or greater perfusion defect on CTPA. Patients were eligible to be treated as outpatients if they were hemodynamically stable, not high risk for bleeding, not requiring oxygen therapy, not requiring unfractionated heparin due to renal failure, and not having another indication for hospital admission. Most patients were treated with low molecular weight heparin (LMWH) for 5–7 days together with warfarin except for cancer patients who were treated with LMWH alone. All patients were instructed to call the thrombosis service or to go the emergency room if they developed symptoms of new PE or bleeding. Outpatients were seen in follow-up at 1, 4, and 12 weeks in the thrombosis clinic. Inpatient charts were reviewed for demographics and reason for hospital admission. For outpatients, in addition to demographics, charts were reviewed for the three month outcomes of major bleeding, recurrent venous thromboembolism and death. Results: There were a total of 633 patients with PE. 319 were admitted to the hospital whereas 314 (49.7%) were managed entirely as outpatients. The mean age for inpatients was 64 years. Inpatients were admitted for the following reasons: 125 (39%) for concomitant illness, 84 (26%) for hypoxia, 21 (7%) for hemodynamic instability, 14 (4%) for pain control, 1 (0.3%) for thrombolysis, 24 (7%) for other investigations, and 50 (16%) for other or unlcear reasons. For the 314 outpatients the mean age was 55 years and 184 (59%) were female. Eight (2.8%) patients were lost to follow-up. There were 195 (62%) idiopathic PE, 62 (20%) had PE secondary to cancer and 57(18%) to other transient risk factors. There were 247 (79%) patients who were managed with LMWH and warfarin, 51 (16%) managed with LMWH alone and 16 (5%) patients had experimental treatment. At 3 months of follow up there were 3 (1%) patients who developed major hemorrhage (GI bleed, hemoptysis, hemarthrosis), 3 (1%) patients who had objectively documented recurrent thrombosis (1 deep vein thrombosis, 2 PE), and 9 (2.9%) patients died, all of them from cancer progression. None of these events occurred within the first 7 days after diagnosis. Conclusions: To our knowledge this is the largest report of outpatient PE management. In our hospital 50% of ambulatory patients who have a diagnosis of PE are managed entirely as outpatients with a low risk for bleeding or thrombosis recurrence. For those admitted the majority was due to a concomitant illness that required admission itself. Many centres remain hesitant to treat patients with PE in this fashion but will treat patients with deep vein thrombosis as outpatients. Both conditions are at risk of recurrent PE and bleeding but it is not clear how a hospital admission would prevent that from happening. Our findings suggest that uncomplicated PE is not an indication for hospital admission per se. Outpatient management of PE deserves further consideration.


2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Tay Tian En Jason ◽  
Tay Jia Sheng ◽  
Tieng Chek Edward Choke ◽  
Pooja Sachdeva

May–Thurner syndrome (MTS) is an underdiagnosed cause of lower limb deep vein thrombosis (DVT). The clinical prevalence of MTS-related DVT is likely underestimated, particularly in patients with other more recognisable risk factors. MTS is classically described in females between the age group of 20–50 years. In patients with acute iliofemoral thrombosis, medical treatment with anticoagulation alone has been associated with higher risk of postthrombotic syndrome (PTS) and lower iliofemoral patency rates, as compared to endovascular correction. We describe a case of MTS-related extensive iliofemoral DVT occurring in a middle age male who presented with acute onset of left lower limb swelling and pain, complicated by pulmonary embolism. Doppler compression ultrasonography of the left lower limb showed partial DVT extending from the left external iliac to the popliteal veins, and contrasted computed tomography (CT) of the thorax abdomen and pelvis established features of MTS, together with right pulmonary embolism. He was started on low molecular weight heparin (LMWH) and then underwent left lower limb AngioJet pharmacomechanical thrombolysis/thrombectomy, iliac vein stenting, and temporary inferior vena cava (IVC) filter insertion. After the procedure, the patient recovered and improved symptomatically with rapid resolution of this left lower limb swelling and pain. He was switched to an oral Factor Xa inhibitor and was subsequently discharged. After 1-month follow-up, he remained well with stent patency visualised on repeat ultrasound and underwent an uneventful elective IVC filter retrieval with subsequent plans for a 1-year follow-up.


Sign in / Sign up

Export Citation Format

Share Document